Urology Times, Digital Edition, June 2011

Two recent Clinical Forum discussions sought to examine how emerging therapeutic options and evolving treatment standards in non–muscle invasive bladder cancer affect clinical practices and patient outcomes.

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

Data showed a significant association between the C allele of the SNP-765G>C of the PTGS2 gene and BPH.

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

The first patient in the trial will be receiving 67Cu-SAR-bisPSMA in combination with enzalutamide.

The sBLA is supported by data from cohort B of the pivotal QUILT-3.032 trial.